Does previous fundoplication alter the surgical approach to esophageal adenocarcinoma?

European Journal of Cardio-thoracic Surgery

Volumn 34, Issue 5, 2008, Pages 1097-1102

  Casson, Alan G ^a   Madani, Koroush ^a   Mann, Sarika ^a   Zhao, Ronghua ^a   Reeder, Bruce ^a   Lim, Hyun Ja ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adenocarcinoma; Esophagus; Fundoplication

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTROSTOMY; ESOPHAGUS RESECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; STOMACH FUNDOPLICATION; STOMACH FUNDUS; STOMACH TUBE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANASTOMOSIS, SURGICAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGUS; FEMALE; FUNDOPLICATION; GASTRIC FUNDUS; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 54949083426     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.07.059     Document Type: Article

References (25)

1. Lieberman D.A., Oehlke M., and Helfand M. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 92 (1997) 1293-1297
2. Lagergren J., Bergstrom R., Lindgren A., and Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
3. Wong A., and Fitzgerald R.C. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 3 (2005) 1-10
4. Westhoff B., Brontze S., Weston A., McElhinney C., Cherian R., Mayo M.M., Smith H.J., and Sharma P. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 61 (2005) 226-231
5. Buskens C.J., Hulscher J.B.F., van Gulik T.M., ten Kate F.J., and van Lanschot J.J.B. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus. J Surg Res 135 (2006) 337-344
6. Vaninetti N.M., Geldenhuys L., Porter G.A., Risch H., Hainaut P., Guernsey D.L., and Casson A.G. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Mol Carcinog 47 (2008) 275-285
7. Mattioli S., Lugaresi M.L., Pierluigi M., Di Simone M.P., and D'Ovidio F. Review article: indications for anti-reflux surgery in gastroesophageal reflux disease. Aliment Pharmacol Ther 17 Suppl. 2 (2003) 60-67
8. Jamieson G.G., France M., and Watson D.T. Results of laparoscopic antireflux operations in patients who have Barrett's esophagus. Chest Surg Clin North Am 12 (2002) 149-155
9. Abbas A.E., Deschamps C., Cassivi S.D., Allen M.S., Miller D.L., and Pairoleru P.C. Barrett's esophagus: the role of laparoscopic fundoplication. Ann Thorac Surg 77 (2004) 393-396
10. Cowgill S.M., Al-Saadi S., Villadolid D., Zervos E.E., and Rosemurgy A.S. Does Barrett's esophagus impact outcome after laparoscopic Nissen fundoplication?. Am J Surg 192 (2006) 622-626
11. Lao-Siriex P., Roy A., Worrall C., Vowler S.L., Gardiner S., and Fitzgerald R.C. Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomark Prev 15 (2006) 288-293
12. Vallbohmer D., DeMeester S.R., Oh D.S., Banki F., Kuramochi H., Shimizu D., Hagen J.A., Danenberg K.D., Danenberg P.V., Chandrasoma P.T., Peters J.H., and DeMeester T.R. Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol 101 (2006) 1458-1466
13. Bowers S.P., Mattar S.G., Smith C.D., Waring J.P., and Hunter J.G. Clinical and histologic follow-up after antireflux surgery for Barrett's esophagus. J Gastrointest Surg 6 (2002) 532-539
14. Mabrut J.-Y., Baulieux J., Adham M., De La Roche E., Gaudin J.-L., Souquet J.-C., and Ducerf C. Impact of antireflux operation on columnar-lined esophagus. J Am Coll Surg 196 (2003) 60-67
15. Oelschlager B.K., Barreca M., Chang L., Oleynikov D., and Pellegrini C.A. Ann Surg 238 (2003) 458-466
16. Gurski R.R., Peters J.H., Hagen J.A., DeMeester S.R., Bremner C.G., Chandrasoma P.T., and DeMeester T.R. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 196 (2003) 706-713
17. Ye W., Chow W.-H., Lagergren J., Yin L., and Nyren O. Risk of adenocarcinoma of the esophagus in patients with GERD after antireflux surgery. Gastroenterology 121 (2001) 1286-1293
18. Corey K.E., Schmitz S.M., and Shaheen N.J. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus?. Am J Gastroenterol 98 (2003) 2390-2394
19. Tran T., Spechler S.J., Richardson P., and El-Serag H.B. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans' Affairs cohort study. Am J Gastroenterol 100 (2005) 1002-1008
20. Chang E.Y., Morris C.D., Seltman A.K., O'Rourke R.W., Chan B.K., Hunter J.G., and Jobe B.A. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus. Ann Surg 246 (2007) 11-21
21. Csendes A., Burdiles P., Braghetto I., and Korn O. Adenocarcinoma appearing very late after antireflux surgery for Barrett's esophagus: long-term follow-up, review of the literature, and addition of six patients. J Gastrointest Surg 8 (2004) 434-441
22. Casson A.G., Evans S.C., Gillis A., Porter G.A., Veuglers P., Darnton S.J., Guernsey D.L., and Hainaut P. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 125 (2003) 1121-1131
23. Casson A.G., Porter G.A., and Veuglers P.J. Evolution and critical appraisal of anastomotic technique following resection of esophageal adenocarcinoma. Dis Esophagus 15 (2002) 296-302
24. Urschel J.D., Antkowiak J.G., Delacure M.D., and Takita H. Ischaemic conditioning (delay phenomenon) improves esophagogastric anastomotic wound healing in the rat. J Surg Oncol 66 (1997) 254-256
25. Baguma-Nibasheka M., Barclay C., Li A.W., Geldenhuys L., Porter G.A., Blay J., Casson A.G., and Murphy P.R. Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor in human esophageal adenocarcinoma. Mol Carcinog 46 (2007) 971-980